Skip to main content
Equibles

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Position in VRDN — Viridian Therapeutics, Inc.\DE

CIK 861177 NEW YORK, NY
Back to VRDN Full portfolio

Position in VRDN

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$18,368,435
+$993,333 QoQ
Shares Held
999,915
+12.6% QoQ
Ownership
0.883%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#34
of 215 holders
Holding Since
Dec 2022
15 quarters on record
Voting authority Sole 46% Shared 0% None 54%

Common Shares in VRDN Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,443,898,601 across 206 Biotechnology names. VRDN ranks #31 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 3,086,683 $1,533,248,041
2 REGN
Regeneron Pharmaceuticals, Inc.
 716,560 $446,803,817
3 ALNY
Alnylam Pharmaceuticals, Inc.
 727,848 $219,104,078
4 INCY
Incyte Corp
 1,508,720 $171,028,494
5 RVMD
Revolution Medicines, Inc.
 912,335 $170,862,094
6 INSM
INSMED Inc
 1,335,071 $142,345,265
7 IONS
Ionis Pharmaceuticals Inc
 1,454,672 $115,340,938
8 MRNA
Moderna, Inc.
 1,521,849 $106,575,080

All Filings in VRDN

Export CSV
15 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $18,368,435 999,915
2026-03-31 $17,375,102 888,298
2025-12-31 $4,336,878 139,360
2025-09-30 $2,999,184 138,980
2025-06-30 $2,657,650 190,104
2025-03-31 $1,760,081 130,570
2024-12-31 $2,219,540 115,782
2024-09-30 $2,036,033 89,496
2024-06-30 $901,981 69,330
2024-03-31 $495,690 28,309
2023-12-31 $330,206 15,161
2023-09-30 $232,569 15,161
2023-06-30 $561,943 23,621
2023-03-31 $600,917 23,621
2022-12-31 $568,718 19,470